Alnylam Pharmaceuticals (ALNY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.84
- Estimate
- $2.14
- Surprise
- -14.2%
- Revenue (period 2026-06-30)
- $1.29B
- Score at report (before → after)
- 6.5 → 6.8/10
Revenue source: mixed.
How the report landed
Alnylam Pharmaceuticals (ALNY) missed the $2.14 estimate with adjusted EPS of $1.84 — a large 14.2% shortfall. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.8/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALNY Sell at 6.2/10.
2 of the last 4 quarters beat the estimate; this quarter's -14.2% surprise compares with a +156.9% four-quarter average. Next scheduled report: 2027-02-11.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Cyclical risk: PE expanding 1.8x (earnings normalizing)
- Consecutive earnings misses (2)
- Negative news sentiment (-0.56)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $156.65
- Price target
- $269.97
- Stop
- $145.68
- Upside to target
- +72.3%
- Reward-to-risk
- 4.8:1
Forward estimates sit below the trailing run-rate (14.8× forward vs 8.1× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 19 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.
ALNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $21.41B
- P/E (fwd)
- 14.8
- P/E (ttm)
- 8.1
- 52-week range
- $149.18–$479.79
- Off 52-week high
- 67.4%
- RSI (14)
- 19
- Volume vs avg
- 1.11×
- Score today
- 6.2/10